IDEAS home Printed from https://ideas.repec.org/r/wly/hlthec/v16y2007i2p195-209.html

Expected value of information and decision making in HTA

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Simon Eckermann & Andrew Willan, 2011. "Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies," PharmacoEconomics, Springer, vol. 29(7), pages 563-577, July.
  2. Bognar, Katalin & Romley, John A. & Bae, Jay P. & Murray, James & Chou, Jacquelyn W. & Lakdawalla, Darius N., 2017. "The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions," Journal of Health Economics, Elsevier, vol. 51(C), pages 1-12.
  3. Simon Eckermann & Andrew R. Willan, 2016. "Expected Value of Sample Information with Imperfect Implementation," Medical Decision Making, , vol. 36(3), pages 282-283, April.
  4. Haitham Tuffaha & Shelley Roberts & Wendy Chaboyer & Louisa Gordon & Paul Scuffham, 2015. "Cost-Effectiveness and Value of Information Analysis of Nutritional Support for Preventing Pressure Ulcers in High-risk Patients: Implement Now, Research Later," Applied Health Economics and Health Policy, Springer, vol. 13(2), pages 167-179, April.
  5. Samer A. Kharroubi & Alan Brennan & Mark Strong, 2011. "Estimating Expected Value of Sample Information for Incomplete Data Models Using Bayesian Approximation," Medical Decision Making, , vol. 31(6), pages 839-852, November.
  6. Hawre Jalal & Jeremy D. Goldhaber-Fiebert & Karen M. Kuntz, 2015. "Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling," Medical Decision Making, , vol. 35(5), pages 584-595, July.
  7. Stijntje W. Dijk & Eline Krijkamp & Natalia Kunst & Jeremy A. Labrecque & Cary P. Gross & Aradhana Pandit & Chia-Ping Lu & Loes E. Visser & John B. Wong & M. G. Myriam Hunink, 2024. "Making Drug Approval Decisions in the Face of Uncertainty: Cumulative Evidence versus Value of Information," Medical Decision Making, , vol. 44(5), pages 512-528, July.
  8. Andrew R. Willan & Simon Eckermann, 2012. "Accounting For Between‐Study Variation In Incremental Net Benefit In Value Of Information Methodology," Health Economics, John Wiley & Sons, Ltd., vol. 21(10), pages 1183-1195, October.
  9. David O. Meltzer & Ties Hoomans & Jeanette W. Chung & Anirban Basu, 2011. "Minimal Modeling Approaches to Value of Information Analysis for Health Research," Medical Decision Making, , vol. 31(6), pages 1-22, November.
  10. Andrew Willan, 2011. "Sample Size Determination for Cost-Effectiveness Trials," PharmacoEconomics, Springer, vol. 29(11), pages 933-949, November.
  11. Andrew Willan & Simon Eckermann, 2012. "Value of Information and Pricing New Healthcare Interventions," PharmacoEconomics, Springer, vol. 30(6), pages 447-459, June.
  12. Jonathan Karnon & Jill Carlton & Carolyn Czoski-Murray & Kevin Smith, 2009. "Informing disinvestment through cost-effectiveness modelling," Applied Health Economics and Health Policy, Springer, vol. 7(1), pages 1-9, March.
  13. Helen Dakin & Sarah Wordsworth, 2013. "Cost‐Minimisation Analysis Versus Cost‐Effectiveness Analysis, Revisited," Health Economics, John Wiley & Sons, Ltd., vol. 22(1), pages 22-34, January.
  14. Claire McKenna & Karl Claxton, 2011. "Addressing Adoption and Research Design Decisions Simultaneously," Medical Decision Making, , vol. 31(6), pages 853-865, November.
  15. Eric Jutkowitz & Fernando Alarid-Escudero & Karen M. Kuntz & Hawre Jalal, 2019. "The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis," PharmacoEconomics, Springer, vol. 37(7), pages 871-877, July.
  16. Paula K Lorgelly, 2018. "The Impact of Brexit on Pharmaceuticals and HTA," PharmacoEconomics - Open, Springer, vol. 2(2), pages 87-91, June.
  17. Strand,Jon & Siddiqui,Sauleh, 2015. "Value of improved information about forest protection values, with application to rainforest valuation," Policy Research Working Paper Series 7423, The World Bank.
  18. Nikki McCaffrey & Meera Agar & Janeane Harlum & Jonathon Karnon & David Currow & Simon Eckermann, 2015. "Better Informing Decision Making with Multiple Outcomes Cost-Effectiveness Analysis under Uncertainty in Cost-Disutility Space," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-19, March.
  19. Simon Eckermann, 2015. "Kinky Thresholds Revisited: Opportunity Costs Differ in the NE and SW Quadrants," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 7-13, February.
  20. Sabine Elisabeth Grimm & Mark Strong & Alan Brennan & Allan J. Wailoo, 2017. "The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment," PharmacoEconomics, Springer, vol. 35(12), pages 1287-1296, December.
  21. Jennifer Uyei & R. Scott Braithwaite, 2016. "Are There Scenarios When the Use of Non–Placebo-Control Groups in Experimental Trial Designs Increase Expected Value to Society?," Medical Decision Making, , vol. 36(1), pages 20-30, January.
  22. Luke B. Connelly, 2026. "The economics of saturation in qualitative analysis," Quality & Quantity: International Journal of Methodology, Springer, vol. 60(1), pages 2077-2091, February.
  23. Hendrik Koffijberg & Claire Rothery & Kalipso Chalkidou & Janneke Grutters, 2018. "Value of Information Choices that Influence Estimates: A Systematic Review of Prevailing Considerations," Medical Decision Making, , vol. 38(7), pages 888-900, October.
  24. Richard Norman & Bram Roudijk & Marcel Jonker & Elly Stolk & Saskia Knies & Raoh-Fang Pwu & Ciaran O’Neill & Kirsten Howard & Nancy Devlin, 2025. "A Taxonomy for Assessing Whether HRQoL Value Sets Are Obsolete," PharmacoEconomics, Springer, vol. 43(5), pages 473-481, May.
  25. Zafar Zafari & Kristian Thorlund & J. FitzGerald & Carlo Marra & Mohsen Sadatsafavi, 2014. "Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes," PharmacoEconomics, Springer, vol. 32(10), pages 995-1004, October.
  26. Mark Strong & Jeremy E. Oakley & Alan Brennan & Penny Breeze, 2015. "Estimating the Expected Value of Sample Information Using the Probabilistic Sensitivity Analysis Sample," Medical Decision Making, , vol. 35(5), pages 570-583, July.
  27. Paolo Pertile, 2009. "An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography," International Journal of Health Economics and Management, Springer, vol. 9(3), pages 317-332, September.
  28. Mohsen Sadatsafavi & Carlo Marra & Stirling Bryan, 2013. "Two‐Level Resampling As A Novel Method For The Calculation Of The Expected Value Of Sample Information In Economic Trials," Health Economics, John Wiley & Sons, Ltd., vol. 22(7), pages 877-882, July.
  29. Lou Garrison;Ruth Puig-Peiro;Adrian Towse, 2012. "The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?," Occasional Paper 000167, Office of Health Economics.
  30. Janneke Grutters & Marjolein Asselt & Kalipso Chalkidou & Manuela Joore, 2015. "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy," PharmacoEconomics, Springer, vol. 33(1), pages 1-4, January.
  31. Nicolas A. Menzies, 2016. "An Efficient Estimator for the Expected Value of Sample Information," Medical Decision Making, , vol. 36(3), pages 308-320, April.
  32. A C Bouman & A J ten Cate-Hoek & B L T Ramaekers & M A Joore, 2015. "Sample Size Estimation for Non-Inferiority Trials: Frequentist Approach versus Decision Theory Approach," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-14, June.
  33. Andrew R. Willan & Simon Eckermann, 2010. "Optimal clinical trial design using value of information methods with imperfect implementation," Health Economics, John Wiley & Sons, Ltd., vol. 19(5), pages 549-561, May.
  34. Andres Alban & Stephen E. Chick & Martin Forster, 2023. "Value-Based Clinical Trials: Selecting Recruitment Rates and Trial Lengths in Different Regulatory Contexts," Management Science, INFORMS, vol. 69(6), pages 3516-3535, June.
  35. Simon Eckermann & Andrew R. Willan, 2009. "Globally optimal trial design for local decision making," Health Economics, John Wiley & Sons, Ltd., vol. 18(2), pages 203-216, February.
  36. Manuel Gomes & Edmond S.-W. Ng & Richard Grieve & Richard Nixon & James Carpenter & Simon G. Thompson, 2012. "Developing Appropriate Methods for Cost-Effectiveness Analysis of Cluster Randomized Trials," Medical Decision Making, , vol. 32(2), pages 350-361, March.
  37. N. J. Welton & A. E. Ades & D. M. Caldwell & T. J. Peters, 2008. "Research prioritization based on expected value of partial perfect information: a case‐study on interventions to increase uptake of breast cancer screening," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 171(4), pages 807-841, October.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.